Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
Long-term Survival and Cure Fraction in Patients with Advanced Hepatocellular Carcinoma under Immunotherapy in Randomized Controlled Trials and Real-world Data.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Campani Claudia, Shim Ju Hyun, Bouattour Mohamed, Touchefeu Yann, Delhoume Victoria, Rosmorduc Olivier, Pascale Alina, An Jihyun, Lee Han Chu, Regnault Helene, Thabut Dominique, Amaddeo Giuliana, Ningarhari Massih, Ollivier-Hourmand Isabelle, Métivier Chloé, Ronot Maxime, Ntandaja-Wandji Line, Ozenne Violaine, Sidali Sabrina, Marra Fabio, Hollande Clémence, Ganne-Carrié Nathalie, Nahon Pierre, Peron Jean-Marie, Lequoy Marie, Sharma Rohini, Paris Liver Cancer Group, Allaire Manon, Nault Jean-Charles
Аннотация
PURPOSE: Immune checkpoint inhibitors (ICI) can induce long-term survival and even cancer cure in several cancers. Mixture cure models (MCM) estimate the fraction of long-term survivors and cured patients but have not been applied in hepatocellular carcinoma (HCC).
EXPERIMENTAL DESIGN: We identified phase III randomized trials of first-line ICI in advanced HCC with mature follow-up (≥30 months) and analyzed a cohort of patients with HCC treated with atezolizumab-bevacizumab. After reconstructing Kaplan-Meier curves, MCMs estimated the long-term survivors' fraction [overall survival (OS)] and cure fractions [progression-free survival (PFS)].
RESULTS: In HIMALAYA (median follow-up of 60 months), long-term survival was 12.8% [95% confidence interval (CI), 8.5%-18.6%] with durvalumab-tremelimumab versus 5.2% (95% CI, 2.6%-10.2%) with sorafenib; the cure fraction was not assessable. In CheckMate 9DW (median follow-up: 35.2 months), long-term survival was 8.7% (95% CI, 0.2%-81.3%) versus 4.1% (95% CI, 0.1%-66.1%), and cure fractions were 17.8% (95% CI, 12%-25.8%) versus 3.5% (95% CI, 0.7%-16.7%) for nivolumab-ipilimumab and sorafenib/lenvatinib, respectively, with long-term OS estimates remaining exploratory due to limited late numbers at risk. In RATIONALE-301, long-term survival was 25.2% (95% CI, 19.2-32.2) with tislelizumab versus 15.4% (95% CI, 10-22.8) with sorafenib. The IMbrave150 trial was not analyzed due to insufficient follow-up (15.6 months). Among a clinical cohort of 1,581 patients treated with atezolizumab-bevacizumab (median follow-up: 34.7 months), long-term survival was 12.3% (95% CI, 9.3%-16.1%), and the cure fraction was 7.9% (95% CI, 6.3%-9.8%). In 1,187 patients meeting IMbrave150 criteria, long-term survival reached 15.4% (95% CI, 10.6%-18.5%), and the cure fraction was 9.1% (95% CI, 7.3%-11.4%). Albumin-bilirubin score and hepatitis C predicted long-term survival, and albumin and hepatitis C predicted cure.
CONCLUSIONS: Across trials and real-world data, ICI combinations achieve long-term survival in 10% to 15% of patients with advanced HCC, with cure fractions of 7% to 9%.
EXPERIMENTAL DESIGN: We identified phase III randomized trials of first-line ICI in advanced HCC with mature follow-up (≥30 months) and analyzed a cohort of patients with HCC treated with atezolizumab-bevacizumab. After reconstructing Kaplan-Meier curves, MCMs estimated the long-term survivors' fraction [overall survival (OS)] and cure fractions [progression-free survival (PFS)].
RESULTS: In HIMALAYA (median follow-up of 60 months), long-term survival was 12.8% [95% confidence interval (CI), 8.5%-18.6%] with durvalumab-tremelimumab versus 5.2% (95% CI, 2.6%-10.2%) with sorafenib; the cure fraction was not assessable. In CheckMate 9DW (median follow-up: 35.2 months), long-term survival was 8.7% (95% CI, 0.2%-81.3%) versus 4.1% (95% CI, 0.1%-66.1%), and cure fractions were 17.8% (95% CI, 12%-25.8%) versus 3.5% (95% CI, 0.7%-16.7%) for nivolumab-ipilimumab and sorafenib/lenvatinib, respectively, with long-term OS estimates remaining exploratory due to limited late numbers at risk. In RATIONALE-301, long-term survival was 25.2% (95% CI, 19.2-32.2) with tislelizumab versus 15.4% (95% CI, 10-22.8) with sorafenib. The IMbrave150 trial was not analyzed due to insufficient follow-up (15.6 months). Among a clinical cohort of 1,581 patients treated with atezolizumab-bevacizumab (median follow-up: 34.7 months), long-term survival was 12.3% (95% CI, 9.3%-16.1%), and the cure fraction was 7.9% (95% CI, 6.3%-9.8%). In 1,187 patients meeting IMbrave150 criteria, long-term survival reached 15.4% (95% CI, 10.6%-18.5%), and the cure fraction was 9.1% (95% CI, 7.3%-11.4%). Albumin-bilirubin score and hepatitis C predicted long-term survival, and albumin and hepatitis C predicted cure.
CONCLUSIONS: Across trials and real-world data, ICI combinations achieve long-term survival in 10% to 15% of patients with advanced HCC, with cure fractions of 7% to 9%.
Предметные рубрики MeSH
HumansCarcinoma, HepatocellularLiver NeoplasmsRandomized Controlled Trials as TopicAntibodies, Monoclonal, HumanizedFemaleAntineoplastic Combined Chemotherapy ProtocolsMaleMiddle AgedAgedImmune Checkpoint InhibitorsImmunotherapyBevacizumabSorafenibClinical Trials, Phase III as TopicAntibodies, Monoclonal